TABLE 1.
A study subject summary data table
| Age (years) (n = 309) | 31.9 ± 10.9 | |||
|---|---|---|---|---|
| History of confirmed infection with SARS‐CoV‐2 or the diagnosis of COVID‐19 (% in n = 309) | 3 (0.0) | |||
| Observed event counts (%) | ||||
| First dose (n = 308) | Second dose (n = 308) | Third dose (n = 305) | ||
| Abnormal bleeding | 2 (0.6) | 3 (1.0) | 9 (3.0) | |
| Irregular menstrual cycle | 6 (1.9) | 15 (4.9) | 20 (6.6) | |
| Injection site local reactions | Pain | 258 (83.8) | 268 (87.0) | 263 (86.2) |
| Swelling | 117 (38.0) | 133 (43.2) | 120 (39.3) | |
| Redness | 65 (21.1) | 85 (27.6) | 62 (20.3) | |
| Itch | 41 (13.3) | 55 (17.9) | 54 (17.7) | |
| Systemic extra injection site reactions | Fatigue | 105 (34.1) | 207 (67.2) | 221 (72.4) |
| Headache | 53 (17.2) | 133 (43.2) | 150 (49.2) | |
| Myalgia | 41 (13.3) | 75 (24.4) | 101 (33.1) | |
| Chill | 36 (11.7) | 113 (36.7) | 141 (46.2) | |
| Fever | 56 (18.2) | 167 (54.2) | 186 (61.0) | |
| Pharyngeal irritation/pain | 5 (1.6) | 14 (4.5) | 32 (10.5) | |
| Arthralgia | 36 (11.7) | 96 (31.1) | 116 (38.0) | |
| Nausea/vomiting | 5 (1.6) | 24 (7.8) | 29 (9.5) | |
| Diarrhea | 7 (2.3) | 14 (4.5) | 16 (5.6) | |
| Abdominal pain | 5 (1.6) | 11 (3.6) | 11 (3.6) | |
| Skin rashes | 1 (0.3) | 2 (0.6) | 4 (1.3) | |
| Perioral abnormal sensation/numbness | 0 (0.0) | 1 (0.3) | 1 (0.3) | |
| Lymphadenopathy | 9 (2.9) | 21 (6.8) | 81 (26.6) | |
| Facial flush | 14 (4.5) | 28 (9.1) | 41 (13.4) | |
| Others | 1 (0.3) | 2 (0.6) | 13 (4.3) | |